Literature DB >> 14561081

Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching.

Santiago Conde1, Daniel I Pérez, Ana Martínez, Concepción Perez, Francisco J Moreno.   

Abstract

Glycogen synthase kinase (GSK-3beta) plays a crucial role in Alzheimer's disease (AD). Its inhibition is a valid approach to the treatment of AD. In this initial letter, some thienyl and phenyl alpha-halomethyl ketones are described as new non-ATP competitive inhibitors of GSK-3beta. They are considered as lead compounds for designing and synthesizing new series, to carry out SAR studies, clear up the mechanism of action, and, in general, evaluate their therapeutical usefulness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561081     DOI: 10.1021/jm034108b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.

Authors:  Chandra Sekhar Kuruva; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2016-10-27       Impact factor: 7.851

2.  Adenylate cyclase regulates elongation of mammalian primary cilia.

Authors:  Young Ou; Yibing Ruan; Min Cheng; Joanna J Moser; Jerome B Rattner; Frans A van der Hoorn
Journal:  Exp Cell Res       Date:  2009-07-02       Impact factor: 3.905

Review 3.  Glycogen synthase kinase 3: more than a namesake.

Authors:  Geetha Vani Rayasam; Vamshi Krishna Tulasi; Reena Sodhi; Joseph Alex Davis; Abhijit Ray
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

4.  Allosteric regulation of glycogen synthase kinase 3β: a theoretical study.

Authors:  Idit Buch; Dan Fishelovitch; Nir London; Barak Raveh; Haim J Wolfson; Ruth Nussinov
Journal:  Biochemistry       Date:  2010-12-03       Impact factor: 3.162

5.  Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

Authors:  Ana Martinez; Carmen Gil; Daniel I Perez
Journal:  Int J Alzheimers Dis       Date:  2011-06-30

6.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS.

Authors:  Hagit Eldar-Finkelman; Ana Martinez
Journal:  Front Mol Neurosci       Date:  2011-10-31       Impact factor: 5.639

7.  Conditional deletion of Rcan1 predisposes to hypertension-mediated intramural hematoma and subsequent aneurysm and aortic rupture.

Authors:  Silvia Villahoz; Paula Sofía Yunes-Leites; Nerea Méndez-Barbero; Katia Urso; Elena Bonzon-Kulichenko; Sagrario Ortega; J Francisco Nistal; Jesus Vazquez; Stefan Offermanns; Juan Miguel Redondo; Miguel R Campanero
Journal:  Nat Commun       Date:  2018-11-15       Impact factor: 14.919

8.  gem-Difunctionalization of α-diazoarylketones with diaryldiselenides and N-halosuccinimides: facile synthesis of α-halo-α-arylseleno ketones.

Authors:  Jiuling Li; Dong Xing; Wenhao Hu
Journal:  Mol Divers       Date:  2020-05-14       Impact factor: 2.943

Review 9.  Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Authors:  Mukesh K Pandey; Timothy R DeGrado
Journal:  Theranostics       Date:  2016-02-17       Impact factor: 11.556

10.  Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3.

Authors:  Paula Martínez de Iturrate; Victor Sebastián-Pérez; Montserrat Nácher-Vázquez; Catherine S Tremper; Despina Smirlis; Julio Martín; Ana Martínez; Nuria E Campillo; Luis Rivas; Carmen Gil
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.